COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al

Ann Rheum Dis. 2022 Oct;81(10):e191. doi: 10.1136/annrheumdis-2020-218713. Epub 2020 Aug 12.

Milena Gianfrancesco¹, Kimme L Hyrich², Jinoos Yazdany¹, Pedro M Machado^{3

4}, Philip C Robinson^{5

6}

¹ Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA.
² Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK.
³ MRC Centre for Neuromuscular Diseases, University College London, London, UK.
⁴ Rheumatology, University College London Centre for Rheumatology, London, UK.
⁵ Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia [email protected].
⁶ Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia.

No abstract available

Keywords: ankylosing; arthritis; lupus erythematosus; rheumatoid; spondylitis; systemic.

Publication types